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Ciprofloxacin Enhances the Stimulation of
Matrix Metalloproteinase 3 Expression by Interleukin-1 in
Human Tendon-Derived Cells
A Potential Mechanism of Fluoroquinolone-Induced Tendinopathy
Anthony N. Corps,1 Rebecca L. Harrall,1 Valerie A. Curry,1 Steven A. Fenwick,2
Brian L. Hazleman,1 and Graham P. Riley1
Objective. To determine whether the fluoroquino-
lone antibiotic ciprofloxacin, which can cause tendon
pain and rupture in a proportion of treated patients,
affects the expression of matrix metalloproteinases
(MMPs) in human tendon-derived cells in culture.
Methods. Cell cultures were derived from 6 sepa-
rate tendon explants, and were incubated in 6-well
culture plates for 2 periods of 48 hours each, with
ciprofloxacin (or DMSO in controls) and interleukin-1
(IL-1), alone and in combination. Samples of super-
natant medium from the second 48-hour incubation
were assayed for MMPs 1, 2, and 3 by Western blotting.
RNA was extracted from the cells and assayed for MMP
messenger RNA (mRNA) by semiquantitative reverse
transcription–polymerase chain reaction, with normal-
ization for GAPDH mRNA.
Results. Unstimulated tendon cells expressed low
or undetectable levels of MMP-1 and MMP-3, and
substantial levels of MMP-2. IL-1 induced a substan-
tial output of both MMP-1 and MMP-3 into cell super-
natants, reflecting increases (typically 100-fold) in
MMP mRNA, but had only minor effects on MMP-2
expression. Ciprofloxacin had no detectable effect on
MMP output in unstimulated cells. Preincubation with
ciprofloxacin potentiated IL-1–stimulated MMP-3
output, reflecting a similar effect on MMP-3 mRNA
expression. Ciprofloxacin also potentiated IL-1–
stimulated MMP-1 mRNA expression, but did not po-
tentiate the output of MMP-1, and had no significant
effects on MMP-2 mRNA expression or output.
Conclusion. Ciprofloxacin can selectively enhance
MMP expression in tendon-derived cells. Such effects
might compromise tendon microstructure and integrity.
The fluoroquinolone antibiotics are a group of
broad-spectrum antibiotics that target the bacterial en-
zyme DNA gyrase, and have been used widely and
successfully. The reported side effects associated with
the use of these antibiotics include tendon pain and/or
rupture in a small proportion of patients, principally
affecting the Achilles tendons (1). Although other ad-
verse reactions, which have been observed in the central
nervous system and gastrointestinal tract, may involve
antagonism of amino acid neurotransmitter receptors
(2), the cellular interactions underlying the effects of
fluoroquinolones on the tendons are not clear. Inflam-
mation of the paratenon and degenerative changes in
tendon cells have been noted in studies of
fluoroquinolone-treated animals (3,4). Fluoroquino-
lones have been shown to have a number of effects on
various mammalian cell types in culture, including both
increased and decreased expression of inflammatory
mediators (5,6), reduced expression of some extracellu-
lar matrix proteins (7,8), reduced mitochondrial activity
(8), and noncytotoxic inhibition of canine tendon cell
proliferation (7).
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The cells of the tendon, predominantly fibro-
blasts, are responsible for the maintenance of the extra-
cellular matrix. This may involve the modification and
turnover of extracellular matrix components, including
collagen cross-linking, breakdown, and resynthesis, es-
pecially in those tendons that are subject to overuse
(9,10). A large part of this remodeling is likely to be
mediated by the group of enzymes known as matrix
metalloproteinases (MMPs) (10,11). The level of MMP
activity in a tissue can be regulated by changes in gene
expression, by the cleavage of latent MMP precursors,
and by association of the MMP with inhibitory proteins
(11). We have previously described differences in the
expression of certain MMPs between normal and degen-
erate human tendons, consistent with a role in tendon
pathology (12).
In cultured canine tenocytes, the fluoroquinolone
ciprofloxacin decreased matrix synthesis and increased
the release of matrix-degrading proteolytic (caseinase)
activity (7). In this study, we have examined whether
ciprofloxacin can influence the expression of MMPs in
human tendon-derived cells in culture.
MATERIALS AND METHODS
Materials. Ciprofloxacin was a gift from Bayer (New-
bury, UK) and a stock (10 mg/ml) was prepared on each day of
use by warming in DMSO. Interleukin-1 (IL-1) was a gift
from Glaxo Wellcome (Stevenage, UK) and aliquots (1 g/ml)
were stored at 70°C. Dulbecco’s modified Eagle’s medium
(DMEM), fetal calf serum (FCS), antibiotics, TRIzol, Western
Breeze immunodetection system, and oligonucleotide primers
for reverse transcription–polymerase chain reaction (RT-
RCR) were obtained from Invitrogen (Paisley, UK). One-Step
RT-PCR reagents and FAM-labeled oligonucleotide probes
were obtained from Applied Biosystems (Warrington, UK).
The anti–MMP-1 antibody used for Western blotting was a
rabbit polyclonal antibody described previously (13), and other
primary and secondary antibodies were obtained from TCS
Biologicals (Buckingham, UK) and Dako (Ely, UK).
Cell isolation and incubation. Tendon specimens were
obtained from tissue discarded during surgery for chronic
tendinopathy, following documentation of patient consent and
local ethics committee approval. Cells, isolated by outgrowth
from 6 separate tendon explants, were maintained and pas-
saged in DMEM containing 10% (volume/volume) FCS, pen-
icillin, streptomycin, and 25 mM HEPES, and were used at
passages between 3 and 8. Cells were seeded at 105/well in
6-well plates, and were incubated for 3 days before the
experiment. They were rinsed with 2 ml of serum-free medium
containing insulin, transferrin, and selenium, or with medium
containing 10% FCS, and were then given 2 ml of the same
medium containing ciprofloxacin (50 g/ml; 0.5% [v/v] DMSO
in control wells), with or without IL-1 (1 ng/ml). After 48
hours, the cells were again rinsed and given fresh medium
containing ciprofloxacin (DMSO in controls) with or without
IL-1. After a further 48 hours, the supernatant medium was
removed and stored at 20°C, and the cells were rinsed with
serum-free medium and solubilized in TRIzol (1 ml/well). In
some of the experiments, cell counts were performed on
parallel wells of cells at the start of the experimental treatment
and at the end of each 48-hour incubation.
Western blotting. Aliquots (20 l) of serum-free cul-
ture supernatants were mixed with sample buffer, boiled for 3
minutes, and subjected to sodium dodecyl sulfate–
polyacrylamide gel electrophoresis under reducing conditions,
using a 10% (weight/volume) polyacrylamide resolving gel with
a 4.5% (w/v) stacking gel. The proteins were electroblotted
onto polyvinylidene difluoride membranes. These were
blocked, incubated with antibodies to MMPs, washed, and
developed using standard protocols, and the films were
scanned and analyzed using 1-dimensional software (Eastman
Kodak, Rochester, NY).
RNA isolation and analysis by RT-PCR. RNA was
isolated from the TRIzol extracts by phenol-chloroform sepa-
ration followed by precipitation with isopropanol and ethanol.
The RNA was stored at 70°C as aliquots, which were thawed
only once, and was assayed for GAPDH, MMP-1, MMP-2, and
MMP-3 messenger RNA (mRNA) using one-step RT-PCR
reactions in a GeneAmp 5700 (Applied Biosystems). All
primers and probes have been described previously (12).
Standard curves were run in each assay using freshly diluted
aliquots of pooled tendon-cell RNA. For each target, this
produced a linear plot of the threshold cycle against the
log(dilution), whose slope was within 10% of the expected
value, indicating a similar, near-maximum efficiency. A single
product of the appropriate size was produced, and no signal
was produced if the reverse transcriptase step was omitted. All
samples from a single experiment were run on the same plate,
generally using either 3 or 4 replicate determinations per
sample. The values obtained for MMP mRNA expression were
corrected for GAPDH mRNA expression in the same sample.
Presentation of data. In each experiment, the values
for MMP-1 and MMP-3 protein or mRNA expression were
normalized to the value for cells treated with IL-1 alone
(after a control preincubation), expressed as 100%. The values
for MMP-2 were normalized to that for cells undergoing
control treatment throughout, expressed as 100%, since
MMP-2 (unlike MMP-1 and MMP-3) was readily detectable in
the control cells. Results were obtained from 6 experiments, 1
from each cell isolate, and significant differences from the
100% value are expressed as the 95% confidence interval (95%
CI) of the treated samples.
RESULTS
Growth of tendon cell cultures. The majority of
the cells in the tendon-derived cultures showed fibro-
blastic morphology that was maintained for at least 8
passages. The cells were seeded at a density just below
confluence, and control cell numbers at the end of the
experiments were within 25% of the initial values;
control cell numbers in serum-free medium frequently
showed a small decrease, while those in medium con-
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taining 10% FCS generally showed a small increase. Of
the treatments tested, only incubation of the cells with
IL-1 for both 48-hour incubations in FCS-containing
medium caused significant changes in cell numbers
(mean SEM final cell number 173 20% of the initial
value, compared with 117  7% in control cell cultures
[n  3]; P  0.05 by t-test). Ciprofloxacin did not cause
significant changes in cell numbers and, in additional
experiments, had no cytotoxic effects at concentrations
up to 100 g/ml (assayed by release of lactate dehydro-
genase; data not shown).
Secretion of MMPs into cell culture superna-
tants. Supernatants from unstimulated tendon cells cul-
tured in serum-free medium showed no immunodetect-
able MMP-1 or MMP-3 on Western blots (Figure 1).
Treatment with IL-1 stimulated the output of both of
these MMPs, in the latent proenzyme form (Figure 1).
This stimulation was at least 50-fold (by comparison with
serial dilutions of MMP standards), and was maintained
or increased when IL-1 was also included in the
preincubation (Figure 2).
Incubation of the cells with ciprofloxacin did not
stimulate detectable output of either MMP-1 or MMP-3
in control cells, but had differential effects on the
stimulation of MMP-1 and MMP-3 output by IL-1
(Figures 1 and 2; compare treatments con/IL1 and
cip/cipIL1). After preincubation with ciprofloxacin,
the induction of MMP-1 output by IL-1 in each exper-
iment either increased by25% or decreased (Figure 2)
(mean difference not significant). In marked contrast,
the stimulation of MMP-3 output by IL-1 was potenti-
ated by ciprofloxacin in each experiment, increasing up
to 3-fold (mean 190%, 95% CI 118–261%). The addition
of ciprofloxacin to cells undergoing continuing stimula-
tion after preincubation with IL-1 had no consistent
effect on either MMP-1 or MMP-3 output (Figure 2).
In addition to MMP-1 and MMP-3, we examined
the expression of MMPs 2, 7, 9, and 13 by the tendon
cells. MMP-2 secretion by control cells was readily
detected (Figure 1), and showed a small, but significant,
stimulation by IL-1 (mean 146%, 95% CI 111–181%,
increasing to 263%, 95% CI 154–372% when IL-1 was
also included in the preincubation) (Figure 2). Cipro-
floxacin had no significant effect on the output of
MMP-2 from either control or IL-1–stimulated cells
(Figure 2). Neither MMP-7 nor MMP-13 was detected
under any condition tested, while the secretion of
MMP-9 was low and was not affected by either IL-1 or
ciprofloxacin (data not shown).
Expression of mRNA for MMPs 1, 2, and 3. The
expression of MMP mRNA in the tendon cell cultures
was investigated by semiquantitative RT-PCR. Similar
results were obtained in RNA extracted from the serum-
free cultures whose supernatants had been used for
Western blotting (Figures 3a–c), and from parallel cul-
tures in medium containing 10% FCS (Figures 3d–f).
Only low levels of MMP-1 and MMP-3 mRNA were
detected in unstimulated cells, and there was a stimula-
tion (typically 100-fold, up to 10,000-fold) by IL-1,
which persisted when IL-1 was also included in the
preincubation (Figure 3). Consistent with the data for
MMP-2 output, control cells expressed substantial levels
of MMP-2 mRNA. This showed variable modulation by
IL-1 and/or ciprofloxacin, with no overall significant
difference, although stimulation up to 3-fold occurred in
some experiments (Figure 3).
Incubation with ciprofloxacin increased both
MMP-1 and MMP-3 mRNA levels in unstimulated cells
in medium containing 10% FCS; these effects were
significant (P  0.05 by Wilcoxon signed rank test), but
were small (mean 4-fold) compared with those induced
by IL-1 (Figure 3). Consistent with its potentiation of
stimulated MMP-3 output, pretreatment of the cells with
ciprofloxacin potentiated the elevation of MMP-3
mRNA induced by IL-1 in both serum-free and serum-
containing media (mean 182%, 95% CI 137–276% and
mean 265%, 95% CI 160–368%, respectively, of that in
Figure 1. Western blot analysis of matrix metalloproteinase (MMP)
secretion by human tendon-derived cells. Cells in serum-free medium
were treated for 2 periods of 48 hours (48h) with ciprofloxacin (cip)
and/or interleukin-1 (IL1), and supernatants from the second incu-
bation were analyzed by Western blotting. The blots are from a single
experiment and show the bands detected using antibodies specific for
MMP-1 (a), MMP-2 (b), and MMP-3 (c). By comparison with MMP
standards, the principal bands correspond to latent pro–MMP-1 (52
kd), latent and active MMP-2 (72 and 62 kd), and pro–MMP-3 (52 kd).
con  vehicle controls.
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the IL-1–stimulated control cells) (Figure 3). However,
in contrast to its lack of effect on MMP-1 output (Figure
2), pretreatment with ciprofloxacin also potentiated the
stimulation of MMP-1 mRNA expression by IL-1, both
in serum-containing medium (mean 504%, 95% CI
162–847%) (Figure 3d) and in 5 of the 6 experiments in
serum-free medium (mean 228%, 95% CI 88–368%;
mean not significantly increased) (Figure 3a). The addi-
tion of ciprofloxacin to cells undergoing continuing
stimulation after preincubation with IL-1 had no con-
sistent effect on either MMP-1 or MMP-3 mRNA levels
(Figure 3).
DISCUSSION
In this study, we have shown that the antibiotic
ciprofloxacin, which induces tendon pain in some pa-
tients (1) and tendon pathology in rodents (3,4), can
increase MMP expression in human tendon-derived
fibroblasts. Specifically, ciprofloxacin potentiated IL-
1–stimulated expression of MMP-3 at both the mRNA
and protein level. Ciprofloxacin also enhanced the ex-
pression of MMP-1 mRNA in most experiments, fre-
quently more than that of MMP-3 mRNA, but this did
not result in increased output of MMP-1 protein, indi-
cating the potential for additional effects on MMP-1
translation or secretion. Since MMP-1 and MMP-3 are
often coordinately stimulated by inflammatory media-
tors (14,15), as was observed in the present study at the
mRNA level, this is a novel differential effect of this
compound on IL-1–stimulated MMP expression.
Tendon pain and degeneration have been associ-
ated with an increase in the normal turnover of matrix
proteins (9,10,12). MMP-3 has a broad substrate speci-
ficity; it is able to degrade matrix components including
type III collagen and the proteoglycans aggrecan and
versican, and is capable of activating a variety of other
MMPs and pro–tumor necrosis factor (11). However, its
role in tendon physiology and pathology has not been
clearly defined. In tendons from sites exposed to high
mechanical demands, such as the Achilles and supraspi-
natus tendons, the expression and activity of MMP-3 are
high compared with that in normal flexor tendons
(10,12). This activity may be necessary for the mainte-
nance of the matrix in response to repeated microinjury;
a change in the activity of several MMPs has also been
associated with tendon rupture (10). Further evidence
indicating the importance of MMPs in tendon has been
provided by the side-effect profile of broad-spectrum
MMP inhibitors such as marimastat, which has been
shown to induce shoulder- and hand-tendon lesions (16).
Figure 2. Analysis of matrix metalloproteinase (MMP) protein secre-
tion by human tendon-derived cells. Cells in serum-free medium were
treated for 2 periods of 48 hours (48h) with ciprofloxacin (cip) or
interleukin-1 (IL1), and supernatants from the second incubation
were analyzed by Western blotting. Each point represents the normal-
ized scan value from a single experiment, and the broken line shows
the 100% value. For MMP-1 (a) and MMP-3 (c), the scan values were
normalized to those of cells treated with IL-1 after a control
preincubation; for MMP-2 (b), the scan values (combined main bands)
were normalized to those of cells given control treatment throughout.
The results from 6 separate experiments are shown, with each exper-
iment using cells from a separate tendon isolate. con  vehicle controls.
CIPROFLOXACIN ENHANCEMENT OF MMP EXPRESSION 3037
Figure 3. Analysis of matrix metalloproteinase (MMP) mRNA expression in human tendon-derived cells
in serum-free medium (a–c) or medium containing 10% fetal calf serum (d–f). Cells were treated for 2
periods of 48 hours (48h) with ciprofloxacin (cip) or interleukin-1 (IL1). Total RNA was isolated and
analyzed relative to GAPDH mRNA. Each point represents the normalized value from a single
experiment, and the broken line shows the 100% value. For MMP-1 (a and d) and MMP-3 (c and f),
mRNA values were normalized to those of cells treated with IL-1 after a control preincubation; for
MMP-2 (b and e), mRNA values were normalized to those of cells given control treatment throughout.
The results from 6 separate experiments are shown (from which the serum-free supernatants were
analyzed for MMP secretion as shown in Figure 2).
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Whether these effects are mediated by inhibition of
specific MMPs is not yet known, although related met-
alloenzymes may also be implicated. We have not yet
investigated the effects of ciprofloxacin on this diverse
group of metalloenzymes, but we found no significant
effect on the expression of MMP-2, MMP-7, MMP-9,
and MMP-13 in this culture system.
A previous study using canine tenocytes showed
that ciprofloxacin increased secretion of proteolytic ac-
tivity, measured as caseinase activity (7). There are
several differences between the two studies, which may
be due, at least in part, to differences in the cell types
involved or the culture conditions utilized (although it
should be noted that the dose of ciprofloxacin used in
the present study was the same as the highest of the
effective range used in the previous study [7], a range
which was chosen according to serum values observed in
patients undergoing treatment). For example, the pro-
liferation of the canine cells was inhibited by cipro-
floxacin, whereas the human cells in the present study
showed little proliferation and no effect of ciprofloxacin.
Also, active caseinase was secreted by the canine cells,
whereas the major form of MMP-3 secreted in our study
corresponds (by size on Western blotting) to pro–
MMP-3. Finally, the canine cells increased caseinase
activity in response to ciprofloxacin alone, but the
enhancement of MMP-3 secretion by ciprofloxacin ob-
served herein by Western blotting occurred in cells
stimulated with IL-1. However, as shown by our results,
we also found that ciprofloxacin, when added alone,
significantly increased the expression of MMP mRNA
over basal levels; this increase was similar to or greater
than the increase in caseinase activity reported in the
previous study (7), but we estimate that a corresponding
increase in the very low basal level of secreted MMP-3
would not have been detected by Western blotting. We
conclude that the two studies, taken together, indicate
that ciprofloxacin can specifically enhance the expres-
sion of matrix-degrading protease(s).
Achilles tendon pain is not generally associated
with inflammation, at least in the tendon mid-substance
(17), but 2 lines of evidence suggest that the current
model system may be relevant to fluoroquinolone-
induced tendon problems. First, fluoroquinolones have
been shown to induce localized inflammation of the
paratenon surrounding rat Achilles tendon (3). Second,
fluoroquinolones have been shown to enhance the ex-
pression of certain interleukins and other cytokines
(5,6). Our results raise the possibility that a combination
of fluoroquinolone and (fluoroquinolone-induced) in-
flammatory mediators might result in the inappropriate
or unbalanced expression of MMPs. Interestingly, al-
though the mechanisms by which fluoroquinolones ini-
tiate changes in mammalian cells are not known, some
reports have indicated that their effects on interleukin
expression may coincide with an increased activity of
transcription factors, such as activator protein 1 (5),
which are also known to influence expression of MMPs
(14,15). Changes in expression of matrix components
such as collagen and proteoglycans have also been
reported in response to various fluoroquinolones (7,8).
Using the present system, it will be of interest to
determine 1) whether the expression of these genes is
coordinated, and 2) whether other members of the
fluoroquinolone class have similar effects.
Finally, there was some variation between exper-
iments in the degree of enhancement of MMP-1 and
MMP-3 output and mRNA expression by ciprofloxacin.
These observations may reflect differences in the cul-
tured cell populations rather than in the patients from
whom the cells were isolated. However, we conclude
that changes in the expression of MMPs, such as those
that we have observed, could contribute to damage of
tendon microstructure and the onset of pain in patients
susceptible to the effects of fluoroquinolones.
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